These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23295262)

  • 1. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability.
    Ansaldi F; Orsi A; de Florentiis D; Parodi V; Rappazzo E; Coppelli M; Durando P; Icardi G
    Hum Vaccin Immunother; 2013 Mar; 9(3):591-8. PubMed ID: 23295262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.
    Levin Y; Kochba E; Shukarev G; Rusch S; Herrera-Taracena G; van Damme P
    Vaccine; 2016 Oct; 34(44):5262-5272. PubMed ID: 27667332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults: a multicenter, randomized trial.
    Hoon Han S; Hee Woo J; Weber F; Joo Kim W; Ran Peck K; Il Kim S; Hwa Choi Y; Myung Kim J
    Hum Vaccin Immunother; 2013 Sep; 9(9):1971-7. PubMed ID: 23778938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.
    Nicholson KG; Thompson CI; Klap JM; Wood JM; Batham S; Newman RW; Mischler R; Zambon MC; Stephenson I
    Vaccine; 2009 Dec; 28(1):171-8. PubMed ID: 19799843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study.
    Van Damme P; Arnou R; Kafeja F; Fiquet A; Richard P; Thomas S; Meghlaoui G; Samson SI; Ledesma E
    BMC Infect Dis; 2010 May; 10():134. PubMed ID: 20504306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children.
    Kanra G; Marchisio P; Feiterna-Sperling C; Gaedicke G; Lazar H; Durrer P; Kürsteiner O; Herzog C; Kara A; Principi N
    Pediatr Infect Dis J; 2004 Apr; 23(4):300-6. PubMed ID: 15071282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
    Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.
    Ansaldi F; Valle L; de Florentiis D; Parodi V; Murdaca G; Bruzzone B; Durando P; Setti M; Icardi G
    Hum Vaccin Immunother; 2012 Aug; 8(8):1048-52. PubMed ID: 22832261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
    Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study.
    Esposito S; Marchisio P; Montinaro V; Bianchini S; Weverling GJ; Pariani E; Amendola A; Fabiano V; Pivetti V; Zanetti A; Zuccotti GV
    Vaccine; 2012 Nov; 30(49):7005-12. PubMed ID: 23059357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months.
    Esposito S; Marchisio P; Ansaldi F; Bianchini S; Pacei M; Baggi E; Trabattoni D; Icardi G; Principi N
    Vaccine; 2010 Aug; 28(38):6137-44. PubMed ID: 20670909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.
    Cox RJ; Pedersen G; Madhun AS; Svindland S; Sævik M; Breakwell L; Hoschler K; Willemsen M; Campitelli L; Nøstbakken JK; Weverling GJ; Klap J; McCullough KC; Zambon M; Kompier R; Sjursen H
    Vaccine; 2011 Oct; 29(45):8049-59. PubMed ID: 21864624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers.
    de Bruijn IA; Nauta J; Gerez L; Palache AM
    Virus Res; 2004 Jul; 103(1-2):139-45. PubMed ID: 15163502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.
    Bihari I; Pánczél G; Kovacs J; Beygo J; Fragapane E
    Clin Vaccine Immunol; 2012 Dec; 19(12):1943-8. PubMed ID: 23081815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
    Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
    Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.